DDInter93 DDInter1619
Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.
Ropinirole, also known as _ReQuip_, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label], . It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome . In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous formulations of ropinirole .
Anagrelide {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Ropinirole
Anagrelide {u} (Compound) downregulates {v} (Gene) USP22
USP22 {u} (Gene) is downregulated by {v} (Compound) Ropinirole
Anagrelide {u} (Compound) causes {v} (Side Effect) Hepatobiliary disease
Hepatobiliary disease {u} (Side Effect) is caused by {v} (Compound) Ropinirole
Anagrelide {u} (Compound) downregulates {v} (Gene) USP22
USP22 {u} (Gene) is regulated by {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is downregulated by {v} (Compound) Ropinirole
Anagrelide {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is associated with {v} (Gene) IKZF1
IKZF1 {u} (Gene) is upregulated by {v} (Compound) Ropinirole
Anagrelide {u} (Compound) upregulates {v} (Gene) HMG20B
HMG20B {u} (Gene) regulates {v} (Gene) MRPL19
MRPL19 {u} (Gene) is downregulated by {v} (Compound) Ropinirole
Anagrelide {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) upregulates {v} (Gene) NNT
NNT {u} (Gene) is upregulated by {v} (Compound) Ropinirole
Anagrelide {u} (Compound) upregulates {v} (Gene) IKBKE
IKBKE {u} (Gene) regulates {v} (Gene) IKZF1
IKZF1 {u} (Gene) is upregulated by {v} (Compound) Ropinirole
Anagrelide {u} (Compound) upregulates {v} (Gene) HMG20B
HMG20B {u} (Gene) is regulated by {v} (Gene) MLLT11
MLLT11 {u} (Gene) is upregulated by {v} (Compound) Ropinirole
Anagrelide {u} (Compound) upregulates {v} (Gene) RHOA
RHOA {u} (Gene) interacts with {v} (Gene) HTR1A
HTR1A {u} (Gene) is bound by {v} (Compound) Ropinirole
Anagrelide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Ropinirole (Compound)
Anagrelide (Compound) downregulates USP22 (Gene) and USP22 (Gene) is downregulated by Ropinirole (Compound)
Anagrelide (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease (Side Effect) is caused by Ropinirole (Compound)
Anagrelide (Compound) downregulates USP22 (Gene) and USP22 (Gene) is regulated by UBQLN2 (Gene) and UBQLN2 (Gene) is downregulated by Ropinirole (Compound)
Anagrelide (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is associated with IKZF1 (Gene) and IKZF1 (Gene) is upregulated by Ropinirole (Compound)
Anagrelide (Compound) upregulates HMG20B (Gene) and HMG20B (Gene) regulates MRPL19 (Gene) and MRPL19 (Gene) is downregulated by Ropinirole (Compound)
Anagrelide (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) upregulates NNT (Gene) and NNT (Gene) is upregulated by Ropinirole (Compound)
Anagrelide (Compound) upregulates IKBKE (Gene) and IKBKE (Gene) regulates IKZF1 (Gene) and IKZF1 (Gene) is upregulated by Ropinirole (Compound)
Anagrelide (Compound) upregulates HMG20B (Gene) and HMG20B (Gene) is regulated by MLLT11 (Gene) and MLLT11 (Gene) is upregulated by Ropinirole (Compound)
Anagrelide (Compound) upregulates RHOA (Gene) and RHOA (Gene) interacts with HTR1A (Gene) and HTR1A (Gene) is bound by Ropinirole (Compound)